<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327779</url>
  </required_header>
  <id_info>
    <org_study_id>WBDR</org_study_id>
    <nct_id>NCT03327779</nct_id>
  </id_info>
  <brief_title>World Bleeding Disorders Registry</brief_title>
  <acronym>WBDR</acronym>
  <official_title>World Bleeding Disorders Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>World Federation of Hemophilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>World Federation of Hemophilia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The WBDR is an international observational disease registry of patients with hemophilia. It&#xD;
      will provide a platform for a network of hemophilia treatment centres (HTCs) around the world&#xD;
      to collect uniform and standardized patient data and guide clinical practice. With informed&#xD;
      consent from the patient, the WBDR stores anonymous data about the person's disease, such as&#xD;
      hemophilia type and severity, symptoms, and treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The WBDR is a prospective, global registry of patients diagnosed with hemophilia A and B.&#xD;
      Following the success of a pilot study, implementation of the full scale WBDR is underway.&#xD;
      The goals are to enroll at least 200 HTCs from more than 50 countries, and at least 10,000&#xD;
      people with hemophilia, during the first five years, aiming for representation of patients&#xD;
      from around the world and from all levels of access to care. Minimal criteria for&#xD;
      participation of HTCs include access to reliable internet, human resources for data entry and&#xD;
      commitment to long-term enrolment and follow-up of patients. The WBDR database is being&#xD;
      developed through a collaboration between the WFH, Karolinska Institute and Health Solutions.&#xD;
&#xD;
      By combining data from countries around the world, the WBDR will provide a large amount of&#xD;
      real world data, on which researchers can address important scientific and clinical issues.&#xD;
      The World Bleeding Disorders Registry (WBDR) is intended to fill existing gaps in knowledge&#xD;
      by collecting real world data on the patient clinical experience around the globe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of participants recruited</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participating Hemophilia Treatment Centres</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participating countries</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of participating Hemophilia Treatment Centres with Hemophilia A or B&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of participating Hemophilia Treatment Centres with Hemophilia A or B&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Donna Coffin, M.Sc.</last_name>
    <phone>+15148757944</phone>
    <phone_ext>2832</phone_ext>
    <email>dcoffin@wfh.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Ayoub, Ph.D.</last_name>
    <phone>+15148757944</phone>
    <phone_ext>2864</phone_ext>
    <email>eayoub@wfh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>World Federation of Hemophilia</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3G 1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Coffin, M.Sc.</last_name>
      <phone>+15148757944</phone>
      <phone_ext>2832</phone_ext>
      <email>dcoffin@wfh.org</email>
    </contact>
    <contact_backup>
      <last_name>Emily Ayoub, Ph.D.</last_name>
      <phone>+15148757944</phone>
      <phone_ext>2864</phone_ext>
      <email>eayoub@wfh.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

